Acute coronary syndrome. An acute inflammatory syndrome

Saudi Medical Journal

Volumn 27, Issue 12, 2006, Pages 1799-1803

  Elabbassi, Wael ^a   Al Nooryani, Arif ^a  

^a Al Qassimi Hospital   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; IMMUNOGLOBULIN M; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; SCAVENGER RECEPTOR; TROPONIN I;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ACUTE DISEASE; HEART INFARCTION; IMMUNOLOGY; INFLAMMATION; SYNDROME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; SYNDROME;

EID: 39049176568     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kruth HS. The fate lipoprotein cholesterol entering the arterial wall. Curr Opin Lipidol 1997; 8: 246.
2. Camejo G, Hurt-Camejo E, Wiklund O. Association of ApoB Lipoproteins with Arterial Proteoglycans: Pathological Significance and Molecular Basis. Atherosclerosis 1998; 139: 205.
3. Witztum JL, Berliner JA. Oxidized Phospholipids and isoprostanes in atherosclerosis. Curr Opini Lipidol 1998; 9: 441.
4. Ley K, Huo Y. VCAM-1 is critical in Atherosclerosis. J Clin Invest 2001; 107: 1209.
5. Nakashima Y, Raines EW, Plump AS. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis prone sites on the Endothelium in the APO-E deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842.
6. Von DK, Fang ZT, Liva SM. Induction of P-selectin by oxidized lipoproteins separate effects on synthesis and surface expression. Circ Res 1997; 80: 810.
7. Luster AD. Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436.
8. Gu L, Okaida Y, Clinton S. Absence of Monocyte Chemmoattractant protein-1 reduces athrosclerosis in low-density lipoprotein-deficient mice. Moll Cell 1998; 2: 275.
9. Miller YI, Chang MK, Binder CJ: Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003; 14: 437.
10. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK et al. Tlymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995; 92: 3893-3897.
11. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveals a complex role for CD4 in atherosclerosis. Circ Res 2005; 96: 427-434.
12. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H et al. Overexpression of interleukin-10 Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071.
13. Manabe I. Nagai R. Regulation of smooth muscle phenotype. Curr Atheroscler Rep 2003; 5: 214.
14. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque, part I: Evolving concepts. J Am Coll Cardiol 2005; 46: 937-954.
15. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
16. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
17. Piek JJ, Van Der Wal AC, Meuiwissen M, Koch KT, Chamuleau SA, Teeling RT, et al. Plaque inflammation in restenotic coronary lesions of patients with stable or unstable angina. Journal of the American College of Cardiology 2000; 35: 963-967.
18. Mauriello A, Sangiorgi G, Fratoni S, Palmieri G, Bonanno E, Anemona L, et al. Diffuse and Active Inflammation Occurs in Both Vulnerable and Stable Plaques of the Entire Coronary Tree. A Histopathologic Study of Patients Dying of Acute Myocardial Infarction. J Am Coll Cardiol 2005; 45: 1585-1593.
19. ≠-Caligiuri G, Liuzzo G, Biasucci LM, Maseri A. Immune System Activation Follows Inflammation in Unstable Angina: Pathogenic Implications. J Am Coll Cardiol 1998; 32: 1295-304.
20. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182.
21. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
22. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes, a TIMI 11A substudy. Thrombolysis in Myocardial infarction. J Am Coll Cardiol 1998; 31: 1460-1465.
23. Chew DP. Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in porcutaneous coronary intervention. Circulation 2001; 104: 992-997.
24. Müller C, Buettner HJ. Hodgson JM, Marsch S, Perruchoud AP, Roskamm H et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412-1415.
25. Hashimoto H, Kitagawa K, Hougaku H, Etani H, Hori M. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 2004; 35: 1625-1630.
26. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up or 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholosterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
29. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G. Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl Med 2004: 350: 1387-1397.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
31. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT TIMI 22) Investigators. C-reactive protein levels and outcomes after gain therapy. N Engl J Med 2005; 352: 20-28.
32. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
33. Pearson TA, Mensah GA. Alexander RW, Anderson JL, Cannon, III RO, Criqui M, et al. Markers of Inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
34. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980; 93: 480-489.
35. Hazen SL, Heineeke JW. 3-Chlorotyrosine, a specific marker of myeloproxidase-catalyzed oxidation, is markedly elevated in low-density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997; 99: 2075-2081.
36. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications acute coronary syndromes. Am J Pathol 2001; 158: 879-891.
37. Zhang R, Brennan ML, Shen Z, McPherson JC, Schmitt D, Molenda CE, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002; 277: 46116-46122.
38. Podrez EA, Febbraio M, Sheibani N, Schmitt D. Silverstein RL. Hajjar DP et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105: 1095-1108.
39. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase, Science 2002; 296: 2391-2394.
40. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142.
41. Brennan ML, Penn MS, Von Lente F, Nambi V, Shishehbor MH, Aviles RJ et al. Prognostic value of myeloperoxidase. in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
42. Baldus S, Heeschen C, Meiniertz T, Zeiher AM, Eiserich JP, Munzel T et al. CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
43. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression:. involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1309-1314.
44. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived, CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-869.
45. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-369.
46. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes, N Engl J Med 2003; 348: 1104-1111.
47. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
48. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: Locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005; 111: 1355-1361.
49. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
50. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
51. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, et al. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. Circulation 2002; 105: 1760.